Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials : The PIONEER 1 randomized clinical trial as an example
© 2019 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd..
Regulatory guidelines describe the use of estimands in designing and conducting clinical trials. Estimands ensure alignment of the objectives with the design, conduct and analysis of a trial. An estimand is defined by four inter-related attributes: the population of interest, the variable (endpoint) of interest, the way intercurrent events are handled and the population level summary. A trial may employ multiple estimands to evaluate treatment effects from different perspectives in order to address different scientific questions. As estimands may be an unfamiliar concept for many clinicians treating diabetes, this paper reviews the estimand concept and uses the PIONEER 1 phase 3a clinical trial, which investigated the efficacy and safety of oral semaglutide vs placebo, as an example of the way in which estimands can be implemented and interpreted. In the PIONEER 1 trial, two estimands were employed for each efficacy endpoint and were labelled as: (a) the treatment policy estimand, used to assess the treatment effect regardless of use of rescue medication or discontinuation of trial product, and provides a broad perspective of the treatment effect in the population of patients with type 2 diabetes in clinical practice; and (b) the trial product estimand, used to assess the treatment effect if all patients had continued to use trial product for the planned duration of the trial without rescue medication, thereby providing information on the anticipated treatment effect of the medication. Both approaches are complementary to understanding the effect of the studied treatments.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Diabetes, obesity & metabolism - 21(2019), 10 vom: 05. Okt., Seite 2203-2210 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aroda, Vanita R [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.09.2020 Date Revised 29.09.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/dom.13804 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM297862103 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM297862103 | ||
| 003 | DE-627 | ||
| 005 | 20231225092918.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/dom.13804 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0992.xml |
| 035 | |a (DE-627)NLM297862103 | ||
| 035 | |a (NLM)31168921 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aroda, Vanita R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials |b The PIONEER 1 randomized clinical trial as an example |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.09.2020 | ||
| 500 | |a Date Revised 29.09.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. | ||
| 520 | |a Regulatory guidelines describe the use of estimands in designing and conducting clinical trials. Estimands ensure alignment of the objectives with the design, conduct and analysis of a trial. An estimand is defined by four inter-related attributes: the population of interest, the variable (endpoint) of interest, the way intercurrent events are handled and the population level summary. A trial may employ multiple estimands to evaluate treatment effects from different perspectives in order to address different scientific questions. As estimands may be an unfamiliar concept for many clinicians treating diabetes, this paper reviews the estimand concept and uses the PIONEER 1 phase 3a clinical trial, which investigated the efficacy and safety of oral semaglutide vs placebo, as an example of the way in which estimands can be implemented and interpreted. In the PIONEER 1 trial, two estimands were employed for each efficacy endpoint and were labelled as: (a) the treatment policy estimand, used to assess the treatment effect regardless of use of rescue medication or discontinuation of trial product, and provides a broad perspective of the treatment effect in the population of patients with type 2 diabetes in clinical practice; and (b) the trial product estimand, used to assess the treatment effect if all patients had continued to use trial product for the planned duration of the trial without rescue medication, thereby providing information on the anticipated treatment effect of the medication. Both approaches are complementary to understanding the effect of the studied treatments | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Diabetes | |
| 650 | 4 | |a GLP-1 receptor agonists | |
| 650 | 4 | |a PIONEER | |
| 650 | 4 | |a estimand | |
| 650 | 4 | |a oral semaglutide | |
| 650 | 4 | |a regulatory guidance | |
| 650 | 7 | |a Glucagon-Like Peptide-1 Receptor |2 NLM | |
| 650 | 7 | |a semaglutide |2 NLM | |
| 650 | 7 | |a 53AXN4NNHX |2 NLM | |
| 650 | 7 | |a Glucagon-Like Peptides |2 NLM | |
| 650 | 7 | |a 62340-29-8 |2 NLM | |
| 700 | 1 | |a Saugstrup, Trine |e verfasserin |4 aut | |
| 700 | 1 | |a Buse, John B |e verfasserin |4 aut | |
| 700 | 1 | |a Donsmark, Morten |e verfasserin |4 aut | |
| 700 | 1 | |a Zacho, Jeppe |e verfasserin |4 aut | |
| 700 | 1 | |a Davies, Melanie J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes, obesity & metabolism |d 1999 |g 21(2019), 10 vom: 05. Okt., Seite 2203-2210 |w (DE-627)NLM111220432 |x 1463-1326 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2019 |g number:10 |g day:05 |g month:10 |g pages:2203-2210 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/dom.13804 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2019 |e 10 |b 05 |c 10 |h 2203-2210 | ||